arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Merck & Co., Inc.

MRK
$148.72 ▲ +1.90 (+1.29%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
20 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Bullish
auto_awesome

Analytical Summary

Merck & Co., Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $372.1B
Dividend Yield 2.21%
Revenue Growth 1.3% ↘
Op. Margin —
ROIC —
FCF / Share $4.94 ↘
Trailing P/E 20.4x
Price / Book 7.1x
FCF Yield 3.3%
Debt / Equity 0.89
info Valuation on last close. End-of-day price, Nov 9, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$65.01B
↑ +1.3% —
Net Income Profit after all expenses
$18.25B
↑ +6.6% —
FCF / Share Free cash flow per share
$4.94
↓ -30.9% —
Long-Term Debt Long-term obligations
$46.75B
↑ +35.7% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
85
Returns →
94
Financial Health ↑
32
Cash Quality ↓
47

Dividend History

Dividend / share · sourced from SEC filings
$3.28 Latest / share
+5.1% YoY
+5.8% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 6 days ago 20 years · 75 quarters